• President Trump's executive order aims to slash U.S. drug prices by 30-80%, matching the lowest global rates.
  • The policy targets Medicare Part B drugs initially, with potential ripple effects on global pharmaceutical markets.
  • PhRMA warns the move could jeopardize billions in domestic R&D investment while benefiting consumers.

Sweeping Changes to Drug Pricing

President Trump signed an executive order on May 12, 2025 implementing a most-favored-nation policy for pharmaceutical pricing, declaring it would bring "unseen" reductions in prescription costs. The policy mandates that the U.S. pay no more than the lowest price available globally for medications, targeting what Trump called "five to ten times" higher U.S. prices during his Truth Social announcement.

"We're ending the era where American patients subsidize the world's healthcare," Trump stated at the signing ceremony. White House officials project the policy could save trillions over time, though implementation will initially focus on Medicare Part B drugs administered in clinical settings.

Industry Pushback Emerges

Pharmaceutical companies reacted swiftly, with PhRMA CEO Stephen Ubl calling the plan "a bad deal that risks medical innovation." Industry analysts note the order could force difficult choices about R&D budgets, with one executive at a major drugmaker privately conceding "every pipeline project is now under review."

The policy's mechanism remains unclear regarding enforcement timelines, though administration sources suggest a phased rollout beginning Q3 2025. This approach mirrors Trump's 2020 attempt at similar reforms, which faced legal challenges before being withdrawn.

Global Market Implications

Beyond U.S. borders, health policy experts warn of potential price increases in countries currently benefiting from lower drug costs. "This essentially exports U.S. pricing pressure abroad," noted one European health minister who requested anonymity. Meanwhile, Medicare administrators scramble to operationalize the changes, with one CMS official admitting "the logistics are formidable" when reached for comment.

As markets digest the news, pharmaceutical stocks dipped modestly in early trading while healthcare providers saw gains. The long-term impact hinges on whether the administration can implement the policy before potential legal challenges or the 2026 midterm elections reshape the political landscape.